|
|
Volumn 136, Issue 3, 2015, Pages 797-800
|
|
Safety and tolerability of a novel inhaled GATA3 mRNA targeting DNAzyme in patients with TH2-driven asthma
a
b
c
d
e
d
e
f
f
a
a
g
h
i
d
b
g
Vectura GmbH
(Germany)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIASTHMATIC AGENT;
DEOXYRIBOZYME;
INTERLEUKIN 13;
INTERLEUKIN 4;
INTERLEUKIN 5;
MESSENGER RNA;
OLIGONUCLEOTIDE;
PLACEBO;
SB 010;
TRANSCRIPTION FACTOR GATA 3;
UNCLASSIFIED DRUG;
GATA3 PROTEIN, HUMAN;
AREA UNDER THE CURVE;
ASTHMA;
BACKACHE;
BRONCHOSPASM;
CELL DIFFERENTIATION;
CONTROLLED STUDY;
COUGHING;
DIARRHEA;
DRUG BLOOD LEVEL;
DRUG SAFETY;
DRUG TARGETING;
DRUG TOLERABILITY;
ENZYME ACTIVITY;
FORCED EXPIRATORY VOLUME;
FORCED VITAL CAPACITY;
HEADACHE;
HUMAN;
LETTER;
LIMIT OF QUANTITATION;
LUNG TOXICITY;
MAJOR CLINICAL STUDY;
MAXIMUM PLASMA CONCENTRATION;
MYALGIA;
OROPHARYNX PAIN;
PRIORITY JOURNAL;
RHINOPHARYNGITIS;
TH2 CELL;
ANTAGONISTS AND INHIBITORS;
CLINICAL TRIAL;
DRUG ADMINISTRATION;
GENE EXPRESSION;
GENETICS;
INHALATIONAL DRUG ADMINISTRATION;
METABOLISM;
PATHOLOGY;
PHASE 3 CLINICAL TRIAL;
RANDOMIZED CONTROLLED TRIAL;
VITAL CAPACITY;
ADMINISTRATION, INHALATION;
ANTI-ASTHMATIC AGENTS;
AREA UNDER CURVE;
ASTHMA;
DNA, CATALYTIC;
DRUG ADMINISTRATION SCHEDULE;
FORCED EXPIRATORY VOLUME;
GATA3 TRANSCRIPTION FACTOR;
GENE EXPRESSION;
HUMANS;
RNA, MESSENGER;
VITAL CAPACITY;
|
|
EID: 84941174746
PISSN: 00916749
EISSN: 10976825
Source Type: Journal
DOI: 10.1016/j.jaci.2015.02.018 Document Type: Article |
|
Times cited : (46)
|
|
References (9)
|
